Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

829.42 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. 
Via Investor's Business Daily
Topics ETFs
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Via The Motley Fool
Pony.ai Targets Robotaxi Mass Production From Mid-2025: But Retail Sentiment Falters
The company unveiled three seventh-generation robotaxi models developed through its partnerships with Toyota, BAIC, and GAC at the Shanghai International Automobile Industry Exhibition on Wednesday. 
Via Stocktwits
Topics Artificial Intelligence Lawsuit
Exposures Artificial Intelligence Financial Legal
Eli Lilly Sues Four Telehealth Companies Selling Copies Of Its Weight-Loss Drug, Says Report: But Retail Stays Optimistic
According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on Wednesday, alleging that they deceived consumers about “untested, unapproved... 
Via Stocktwits
Topics Lawsuit
Exposures Financial Legal Product Safety
Boston Scientific Stock Jets 8% Higher On Solid Quarterly Beat, Hiked Guidance
Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales view. 
Via Investor's Business Daily
Topics Retirement
Exposures Pension
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
Via Benzinga
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Topics World Trade
Exposures Tariff
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up. 
Via The Motley Fool
Q1 Earnings Season Scorecard And Analyst Reports For Nvidia, Alphabet & Berkshire Hathaway
Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on 16 major stocks, including NVIDIA Corporation, Alphabet Inc., and Berkshire... 
Via Talk Markets
Topics Stocks / Equities
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
Intuitive Surgical Plunges After Saying Tariffs Impact 'Could Be Material'
Intuitive Surgical stock plunged late Tuesday on worries about potential tariffs. The impact "could be material." 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win. 
Via Investor's Business Daily
Exposures Product Safety
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results. 
Via Stocktwits
Exposures Product Safety
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April. 
Via Benzinga
Topics Earnings
Exposures Financial
ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom
Last week, thematic and leveraged ETFs performed well, such as DJTU, LLYX, NFXL, DECO, and MSTY, despite market concerns. Tech sector was hit by geopolitical tension and hawkish central bank comments.... 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
U.S. stock futures declined on Monday after a holiday-shortened week that ended with a mixed close on Thursday. 
Via Benzinga
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Dow Dips Over 500 Points, Down For 3rd Straight Session As UnitedHealth Tanks: Greed Index Remains In 'Extreme Fear' Zone
U.S. stocks end lower, Dow falls over 500 points. Fear & Greed index remains in Extreme Fear zone. Eli Lilly & Co. sees sharp rally on trial results. 
Via Benzinga
Topics Stocks
Exposures US Equities
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.